{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-008922","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.137776+00:00","generated_at":"2026-05-18T17:17:39.742240+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Protalix shareholders elect eight directors, approve advisory compensation, ratify auditor at annual meeting","bullets":["Eight director nominees elected with for votes ranging from 21.3M to 22.6M; broker non-votes ~12.7M.","Non-binding advisory vote on named executive officer compensation passed: 16.4M for, 7.5M against, 0.4M abstain.","Ratification of Kesselman & Kesselman (PwC Israel) as independent auditor for 2025 approved: 34.9M for, 1.6M against.","Broker non-votes of ~12.7M present on director election and compensation proposals."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-008922","json":"https://secwatch.observer/filing/0001558370-25-008922.json","markdown":"https://secwatch.observer/filing/0001558370-25-008922.md","text":"https://secwatch.observer/filing/0001558370-25-008922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025008922/0001558370-25-008922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025008922/plx-20250626x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:17:39.742240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}